Skip to main content
. 2023 Nov 15;32(1):59–73. doi: 10.1016/j.ymthe.2023.11.018

Figure 2.

Figure 2

Construction and infection efficacy to liver of AAV-LPL recombinant viral vector

(A) Structure diagram of AAV-LPL recombinant viral vector. (B) Representative fluorescent images of livers from WT mice treated with different doses of AAV-LPL (n = 6 per group). Scale bar, 100 μm. (C) Representative fluorescent images of various organs from WT mice treated with 1 × 1013 vg/kg AAV-EGFP (n = 6). Scale bar, 100 μm. (D) Expression of human LPL mRNA relative to Gapdh in various tissues of WT mice treated with 1 × 1013 vg/kg AAV-LPL (n = 6). (E) Expression of human LPL mRNA relative to Gapdh in liver from WT mice treated with different doses of AAV-LPL (n = 6 per group). (F) Immunohistochemical analysis of LPL in the liver from WT mice treated with different doses of AAV-LPL (n = 6 per group). Scale bars, 200 and 50 μm. Data are presented as mean ± SEM.